Becker Muscular Dystrophy

Pipeline Programs

Companies

Clinical Trials

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

MedpaceCINCINNATI, OH

3 programs

SevasemtenPhase 21 trial

Sevasemten 10 mgPhase 21 trial

SevasemtenPhase 11 trial

Active Trials

NCT05160415Completed12Est. Mar 2024

NCT06066580Enrolling By Invitation260Est. Feb 2031

NCT05291091Active Not Recruiting244Est. Sep 2026

Santhera PharmaceuticalsSwitzerland - Pratteln

1 program

VamorolonePhase 2

ReveraGen BioPharmaMD - Rockville

1 program

VamorolonePhase 21 trial

Active Trials

NCT05166109Completed46Est. Aug 2025

PfizerNEW YORK, NY

1 program

MYO-029Phase 1/21 trial

Active Trials

NCT00104078Completed108Est. Jan 2007

Epirium BioCA - Sacramento

1 program

Safety and Biomarker Response to (+)-Epicatechin in Becker Muscular DystrophyPhase 11 trial

Active Trials

NCT04386304Completed22Est. Mar 2022

BiocorpFrance - Issoire

1 program

Safety and Biomarker Response to (+)-Epicatechin in Becker Muscular DystrophyPhase 1

Edgewise TherapeuticsBOULDER, CO

4 programs

Defining Endpoints in Becker Muscular DystrophyN/A1 trial

SevasemtenPHASE_1

SevasemtenPHASE_2

Sevasemten 10 mgPHASE_2

Active Trials

NCT05257473Active Not Recruiting80Est. Aug 2026

Lead PharmaNetherlands - Oss

1 program

Evaluation of Limb-Girdle Muscular DystrophyN/A1 trial

Active Trials

NCT00893334CompletedEst. Dec 2013

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

2027

2028

2029

2030

2031

MedpaceSevasemten

MedpaceSevasemten 10 mg

ReveraGen BioPharmaVamorolone

PfizerMYO-029

MedpaceSevasemten

Epirium BioSafety and Biomarker Response to (+)-Epicatechin in Becker Muscular Dystrophy

Edgewise TherapeuticsDefining Endpoints in Becker Muscular Dystrophy

Lead PharmaEvaluation of Limb-Girdle Muscular Dystrophy

Clinical Trials (8)

Total enrollment: 772 patients across 8 trials

NCT06066580 MedpaceSevasemten

Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy

Start: Nov 2023Est. completion: Feb 2031260 patients

Phase 2Enrolling By Invitation

NCT05291091 MedpaceSevasemten 10 mg

Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)

Start: Nov 2022Est. completion: Sep 2026244 patients

Phase 2Active Not Recruiting

NCT05166109 ReveraGen BioPharmaVamorolone

A Study to Assess Vamorolone in Becker Muscular Dystrophy (BMD)

Start: Jul 2022Est. completion: Aug 202546 patients

Phase 2Completed

NCT00104078 PfizerMYO-029

Study Evaluating MYO-029 in Adult Muscular Dystrophy

Start: Feb 2005Est. completion: Jan 2007108 patients

Phase 1/2Completed

NCT05160415 MedpaceSevasemten

A Study of EDG-5506 in Adult Males With Becker Muscular Dystrophy

Start: Dec 2021Est. completion: Mar 202412 patients

Phase 1Completed

NCT04386304 Epirium BioSafety and Biomarker Response to (+)-Epicatechin in Becker Muscular Dystrophy

Safety and Biomarker Response to (+)-Epicatechin in Becker Muscular Dystrophy

Start: Jul 2020Est. completion: Mar 202222 patients

Phase 1Completed

NCT05257473 Edgewise TherapeuticsDefining Endpoints in Becker Muscular Dystrophy

Defining Endpoints in Becker Muscular Dystrophy

Start: Apr 2022Est. completion: Aug 202680 patients

N/AActive Not Recruiting

NCT00893334 Lead PharmaEvaluation of Limb-Girdle Muscular Dystrophy

Evaluation of Limb-Girdle Muscular Dystrophy

Start: Apr 2009Est. completion: Dec 2013

N/ACompleted

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

8 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.